Viking Therapeutics Inc (NASDAQ:VKTX) shares traded up 7.1% on Thursday . The company traded as high as $4.74 and last traded at $4.69. 691,080 shares were traded during mid-day trading, a decline of 22% from the average session volume of 881,833 shares. The stock had previously closed at $4.38.

A number of research analysts have recently weighed in on the company. Maxim Group set a $8.00 price objective on Viking Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 12th. ValuEngine lowered Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Roth Capital began coverage on Viking Therapeutics in a report on Tuesday, November 21st. They set a “buy” rating and a $5.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Viking Therapeutics in a report on Friday, November 10th.

The company has a market cap of $131.39 and a price-to-earnings ratio of -5.52.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). research analysts expect that Viking Therapeutics Inc will post -0.86 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. Sabby Management LLC acquired a new stake in Viking Therapeutics during the second quarter worth about $525,000. Sphera Funds Management LTD. acquired a new stake in Viking Therapeutics during the third quarter worth about $554,000. Virtu KCG Holdings LLC acquired a new stake in Viking Therapeutics during the second quarter worth about $124,000. Creative Planning grew its holdings in Viking Therapeutics by 600.0% during the fourth quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 60,000 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in Viking Therapeutics during the third quarter worth about $108,000. 5.77% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2018/01/18/viking-therapeutics-vktx-trading-7-1-higher.html.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.